Review



abciximab  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    MedChemExpress abciximab
    Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 <t>(abciximab)</t> but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.
    Abciximab, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/abciximab/product/MedChemExpress
    Average 93 stars, based on 7 article reviews
    abciximab - by Bioz Stars, 2026-06
    93/100 stars

    Images

    1) Product Images from "Endo-chip laser-induced thrombus formation: a vessel-on-chip model for in vitro testing of antithrombotic agents"

    Article Title: Endo-chip laser-induced thrombus formation: a vessel-on-chip model for in vitro testing of antithrombotic agents

    Journal: Blood Vessels, Thrombosis & Hemostasis

    doi: 10.1016/j.bvth.2025.100096

    Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 (abciximab) but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.
    Figure Legend Snippet: Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 (abciximab) but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.

    Techniques Used: Inhibition, Incubation, Labeling



    Similar Products

    abciximab  (MedChemExpress)
    93
    MedChemExpress abciximab
    Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 <t>(abciximab)</t> but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.
    Abciximab, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/abciximab/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    abciximab - by Bioz Stars, 2026-06
    93/100 stars
    		  Buy from Supplier
    abciximab  (Biocon Inc)
    90
    Biocon Inc abciximab
    Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 <t>(abciximab)</t> but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.
    Abciximab, supplied by Biocon Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/abciximab/product/Biocon Inc
    Average 90 stars, based on 1 article reviews
    abciximab - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    reopro® (abciximab) antibody  (Centocor Inc)
    90
    Centocor Inc reopro® (abciximab) antibody
    Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 <t>(abciximab)</t> but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.
    Reopro® (Abciximab) Antibody, supplied by Centocor Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/reopro® (abciximab) antibody/product/Centocor Inc
    Average 90 stars, based on 1 article reviews
    reopro® (abciximab) antibody - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    abciximab  (Eli Lilly)
    86
    Eli Lilly abciximab
    Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 <t>(abciximab)</t> but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.
    Abciximab, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/abciximab/product/Eli Lilly
    Average 86 stars, based on 1 article reviews
    abciximab - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    abciximab reopro  (Eli Lilly)
    90
    Eli Lilly abciximab reopro
    Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 <t>(abciximab)</t> but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.
    Abciximab Reopro, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/abciximab reopro/product/Eli Lilly
    Average 90 stars, based on 1 article reviews
    abciximab reopro - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    abciximab  (Mager Scientific)
    90
    Mager Scientific abciximab
    Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 <t>(abciximab)</t> but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.
    Abciximab, supplied by Mager Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/abciximab/product/Mager Scientific
    Average 90 stars, based on 1 article reviews
    abciximab - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    monoclonal antibody abciximab reopro  (Eli Lilly)
    90
    Eli Lilly monoclonal antibody abciximab reopro
    Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 <t>(abciximab)</t> but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.
    Monoclonal Antibody Abciximab Reopro, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monoclonal antibody abciximab reopro/product/Eli Lilly
    Average 90 stars, based on 1 article reviews
    monoclonal antibody abciximab reopro - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    glycoprotein iib/iiia inhibitor abciximab reopro  (Eli Lilly)
    90
    Eli Lilly glycoprotein iib/iiia inhibitor abciximab reopro
    Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 <t>(abciximab)</t> but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.
    Glycoprotein Iib/Iiia Inhibitor Abciximab Reopro, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/glycoprotein iib/iiia inhibitor abciximab reopro/product/Eli Lilly
    Average 90 stars, based on 1 article reviews
    glycoprotein iib/iiia inhibitor abciximab reopro - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 (abciximab) but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.

    Journal: Blood Vessels, Thrombosis & Hemostasis

    Article Title: Endo-chip laser-induced thrombus formation: a vessel-on-chip model for in vitro testing of antithrombotic agents

    doi: 10.1016/j.bvth.2025.100096

    Figure Lengend Snippet: Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 (abciximab) but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.

    Article Snippet: Abciximab (anti-αIIbβ3 inhibitory antibody, clone C7E3) was purchased from MedChemExpress LLC (Monmouth Junction, NJ).

    Techniques: Inhibition, Incubation, Labeling